Paloma Partners’s TherapeuticsMD TXMD Stock Holding History

Paloma Partners’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-346	Closed	-$105K	–	2271
2017 Q4	$105K	Buy	+346	New	+$96.3K	﹤0.01%	1793
2016 Q2	–	Sell	-622	Closed	-$199K	–	2350
2016 Q1	$199K	Buy	+622	New	+$212K	﹤0.01%	1696
2015 Q2	–	Sell	-1,679	Closed	-$508K	–	1952
2015 Q1	$508K	Buy	1,679 +1,345	+403%	+$328K	0.01%	775
2014 Q4	$74K	Buy	+334	New	+$68.9K	﹤0.01%	1082

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Paloma Partners's TXMD Position: Q1 2018 in Review

Paloma Partners sold out of TherapeuticsMD (TXMD) in Q1 2018, closing a stake of 346 shares — an estimated $105K sold.

Paloma Partners first reported a position in TXMD in Q4 2014 and held it in 4 quarters. The position peaked at $508K in Q1 2015. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2018.

Paloma Partners reported no remaining TherapeuticsMD position as of Q1 2018 after selling out during the quarter.
Paloma Partners sold 346 TherapeuticsMD shares in Q1 2018, an estimated $105K.
Paloma Partners first reported a position in TherapeuticsMD in Q4 2014 and held it in 4 quarters.
Paloma Partners's TherapeuticsMD position peaked at $508K in Q1 2015.
143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2018.

Based on Paloma Partners's 13F filing for Q1 2018, filed 15 May 2018.